Browsing by Author "Pavlidis, Nicholas"
Now showing items 41-60 of 442
-
Article
Cancer treatment reviews welcomes submission of the Cochrane Reviews
Pavlidis, Nicholas; Stahel, R. A.; Clarke, M.; Djulbegovic, B. (2006)
-
Article
Cancer, fertility and pregnancy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Pentheroudakis, George; Orecchia, R.; Hoekstra, H. J.; Pavlidis, Nicholas (2010)
-
Article
Cancer, fertility and pregnancy: ESMO Clinical Recommendations for diagnosis, treatment and follow-up
Pentheroudakis, George; Pavlidis, Nicholas; Castiglione, M. (2009)
-
Article
Cancer, fertility and pregnancy: ESMO clinical recommendations for diagnosis, treatment and follow-up
Pentheroudakis, George; Pavlidis, Nicholas; Castiglione, M. (2008)
-
Article
Cancer, pregnancy and fertility: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Peccatori, Fedro A.; Azim, Hatem A.; Orecchia, R.; Hoekstra, H. J.; Pavlidis, Nicholas; Kesic, V.; Pentheroudakis, George (2013)
-
Article
Cancers of unknown primary site: ESMO clinical practice guidelines for diagnosis, treatment and follow-up
Pavlidis, Nicholas; Briassoulis, E. Ch; Pentheroudakis, George (2010)
-
Article
Cancers of unknown primary site: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Fizazi, K.; Greco, F. A.; Pavlidis, Nicholas; Daugaard, G.; Oien, K.; Pentheroudakis, George; ESMO Guidelines Committee (2015)
-
Article
Cancers of unknown primary site: ESMO clinical practice guidelines for diagnosis, treatment and follow-up
Fizazi, K.; Greco, F. A.; Pavlidis, Nicholas; Pentheroudakis, George (2011)
-
Article
Cancers of unknown primary site: ESMO clinical recommendation for diagnosis, treatment and follow-up
Briassoulis, E. Ch; Pavlidis, Nicholas; Felip, E. (2008)
-
Article
Cancers of unknown primary site: ESMO clinical recommendations for diagnosis, treatment and follow-up
Briassoulis, E. Ch; Pavlidis, Nicholas; Felip, E. (2009)
-
Article
Cancers of unknown primary site: ESMO Clinical Recommendations for diagnosis, treatment and follow-up
Briassoulis, E. Ch; Pavlidis, Nicholas (2007)
-
Article
Carboplatin alone compared with its combination with epirubicin and cyclophosphamide in untreated advanced epithelial ovarian cancer: A hellenic co-operative oncology group study
Skarlos, Dimosthenis V.; Aravantinos, Gerasimos; Kosmidis, Paraskevas A.; Pavlidis, Nicholas; Gennatas, Constantinos; Beer, M.; Mylonakis, N.; Makrantonakis, P.; Klouvas, G. D.; Karpathios, S.; Linardou, H.; Konstantaras, C.; Fountzilas, George (1996)We compared, in a multicentric randomised prospective study, the efficacy and toxicity of carboplatin 400 mg/m2 as a single agent (CB) to a combination of carboplatin 300 mg/m2, epirubicin 50 mg/m2 and cyclophosphamide 500 ...
-
Article
Carboplatin plus paclitaxel in unknown primary carcinoma: A phase II Hellenic Cooperative Oncology Group Study
Briassoulis, E. Ch; Kalofonos, H. P.; Bafaloukos, Dimitrios; Samantas, E.; Fountzilas, George; Xiros, N.; Skarlos, Dimosthenis V.; Christodoulou, C.; Kosmidis, Paraskevas A.; Pavlidis, Nicholas (2000)Purpose: To evaluate the efficacy of the carboplatin/paclitaxel combination in patients with carcinoma of unknown primary site (CUP). Patients and Methods: Seventy-seven consecutive CUP patients (45 women and 32 men; median ...
-
Article
Carcinoma of unknown primary (CUP)
Pavlidis, Nicholas; Fizazi, K. (2009)Carcinoma of unknown primary (CUP) is one of the 10 most frequent cancers worldwide. It constitutes 3-5% of all human malignancies. Patients with CUP present with metastases without an established primary site. CUP manifests ...
-
Article
Carcinoma of unknown primary: Natural history and treatment. Analysis of 30 cases and review of the literature
Pavlidis, Nicholas; Sourla, A.; Ch, F. Tolis; Theoharis, N. M.; Nikolaou, N. (1990)In this study, the natural history and therapeutic management of 30 patients with carcinoma of unknown primary (CUP syndrome) is presented. Despite detailed laboratory investigations, the primary occult tumor was not ...
-
Article
Carzelesin phase II study in advanced breast, ovarian, colorectal, gastric, head and neck cancer, non-Hodgkin's lymphoma and malignant melanoma: A study of the EORTC early clinical studies group (ECSG)
Pavlidis, Nicholas; Aamdal, S.; Awada, Ahmad; Calvert, H.; Fumoleau, P.; Sorio, R.; Punt, C.; Verweij, J.; Oosterom, A. T. Van; Morant, R.; Wanders, J.; Hanauske, A. R. (2000)Purpose: In a phase II trial, the activity of carzelesin, a cyclopropylpyrroloindole prodrug analog, was assessed. Patients and methods: Carzelesin was used as second- or third-line chemotherapy in patients with breast, ...
-
Article
Cavitating squamous cell lung carcinoma-distinct entity or not? Analysis of radiologic, histologic, and clinical features
Pentheroudakis, George; Kostadima, Lida; Fountzilas, George; Kalogera-Fountzila, Anna; Klouvas, G. D.; Kalofonos, H. P.; Pavlidis, Nicholas (2004)Introduction: Patients with cavitating squamous lung carcinoma (cSLC) are believed to harbor aggressive, chemoresistant disease with distinct features and fare poorly. We retrospectively analyzed radiologic, histologic, ...
-
Article
CENP-B specific anti-centromere autoantibodies heralding small-cell lung cancer. A case study and review of the literature
Briassoulis, E. Ch; Kamposioras, K.; Tzovaras, V.; Pafitanis, G.; Kostoula, A.; Mavridis, A. K.; Pavlidis, Nicholas (2008)We report on a small-cell lung cancer case that was heralded by the presence of CENP-B specific anti-centromere autoantibodies (ACA) detected well before the diagnosis of cancer. The patient received chemotherapy plus ...
-
Article
CEOP-21 versus CEOP-14 chemotherapy with or without rituximab for the first-line treatment of patients with aggressive lymphomas: Results of the HE22A99 trial of the hellenic cooperative oncology group
Economopoulos, T.; Psyrri, A.; Dimopoulos, M. A.; Kalogera-Fountzila, Anna; Pavlidis, Nicholas; Tsatalas, C.; Nikolaides, C.; Mellou, S.; Xiros, N.; Fountzilas, George (2007)Background: In this study we investigated whether administering CEOP (cyclophosphamide, epirubicin, vincristine [Oncovin], and prednisone) every 2 weeks (CEOP-14) instead of every 3 weeks (the standard CEOP-21 regimen) ...
-
Book Chapter
Cervical lymph node metastases of squamous cell carcinoma from an unknown primary site
Pavlidis, Nicholas; Plataniotis, G. (Springer International Publishing, 2016)Cancer of unknown primary (CUP) is a well-recognized clinical disorder where the primary site cannot be identified after a standard diagnostic approach and it accounts for 3-5 % of all tumors. CUP is distinguished into two ...